<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005049</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067641</org_study_id>
    <secondary_id>P30CA016087</secondary_id>
    <secondary_id>NYU-9645</secondary_id>
    <secondary_id>NCI-G00-1717</secondary_id>
    <nct_id>NCT00005049</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer</brief_title>
  <official_title>Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug and giving them by intraperitoneal&#xD;
      infusion may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of intraperitoneal combination&#xD;
      chemotherapy in treating patients who have stage III ovarian epithelial cancer or&#xD;
      gastrointestinal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess tolerance and complications from consolidation therapy with intraperitoneal&#xD;
           floxuridine and cisplatin and/or carboplatin in patients with stage III ovarian&#xD;
           epithelial cancer or gastrointestinal cancer with peritoneal involvement.&#xD;
&#xD;
        -  Determine the sites of failure and estimate the time to failure following treatment with&#xD;
           this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of residual disease at second look&#xD;
      laparotomy or laparoscopy (micro only vs no greater than 0.5 cm vs greater than 0.5 cm and no&#xD;
      greater than 1 cm), and by CA-125 level (elevated vs normal on day -7).&#xD;
&#xD;
      Patients receive intraperitoneal floxuridine on days 1-3 followed by intraperitoneal&#xD;
      cisplatin and/or carboplatin on day 3. Treatment continues every 3 weeks for 4-6 courses in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 and 6 weeks, then at 6, 12, 18, and 24 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study over 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">45</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage III ovarian epithelial cancer or&#xD;
             gastrointestinal cancer with peritoneal involvement&#xD;
&#xD;
          -  Patients with ovarian cancer must have completed first induction treatment with a&#xD;
             platinum based regimen (carboplatin and/or cisplatin) and be in clinical complete&#xD;
             response at time of assessment for study&#xD;
&#xD;
          -  No ovarian cancer of low malignant potential&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT less than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No underlying medical or psychiatric condition that precludes informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Laparoscopy or laparotomy required within 8 weeks of study to assess residual disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco M. Muggia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

